Opinion
Video
Author(s):
Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.
TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Osimertinib Plus Chemotherapy Moves One Step Closer to EU Approval in EGFR+ Advanced NSCLC
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Dato-DXd Demonstrates Intracranial Activity in Advanced NSCLC With/Without Brain Metastases
Updated CheckMate 816 Data Reinforce Neoadjuvant Nivolumab/Chemo as a SOC for Resectable NSCLC
Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML
Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC
High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab
Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer